Trabectedin Combined With Durvalumab (MEDI4736) in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. A Phase Ib Study.
Phase of Trial: Phase I
Latest Information Update: 18 May 2017
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Trabectedin (Primary)
- Indications Ovarian cancer; Soft tissue sarcoma
- Focus Adverse reactions
- Acronyms TRAMUNE
- 12 May 2017 Planned End Date changed from 15 May 2021 to 5 May 2021.
- 12 May 2017 Planned primary completion date changed from 15 May 2020 to 5 May 2020.
- 12 May 2017 Status changed from not yet recruiting to recruiting.